Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(40%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_1
1
20%
Ph phase_3
1
20%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Other(2)

Detailed Status

unknown2
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

unknown240%
completed120%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126
completedphase_1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

NCT02723955
recruitingnot_applicable

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

NCT04519905
unknownphase_2

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

NCT02943798
unknownphase_2

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

NCT01276769

Clinical Trials (5)

Showing 5 of 5 trials
NCT06743126Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
NCT02723955Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed
NCT04519905Not Applicable

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Recruiting
NCT02943798Phase 2

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Unknown
NCT01276769Phase 2

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5